Symbol not found

NYSE:PFE   00:00AM GMT
0.00
0.00 (0.00%)
Products, Other Pre-Announcement

Roivant And Pfizer Unveil Priovant Therapeutics And Ongoing Registrational Studies For Oral Brepocitinib In Dermatomyositis And Lupus

Published: 06/28/2022 11:32 GMT
Pfizer Inc. (PFE) - Roivant and Pfizer Unveil Priovant Therapeutics and Ongoing Registrational Studies for Oral Brepocitinib in Dermatomyositis and Lupus.
Pfizer Inc - an Phase 2b Study in Sle, Designed to Serve As One of Two Registrational Studies, is Expected to Generate Top-line Results in 2h 2023.
Pfizer - in Five Placebo-controlled Studies Completed to Date, Oral Brepocitinib Generated Statistically Significant & Clinically Meaningful Results.